kras mutation and glutathion KRAS-targeted therapies in cancer: novel approaches overcoming resistance KRAS | OriGene Technologies Inc.
KRAS OriGene Technologies Inc. KRAS mutation: from undruggable to druggable in cancer Signal Transduction and Targeted Therapy BRAFV600E in colorectal cancer reduces sensitivity to oxidative stress and promotes site specific metastasis by stimulating glutathione synthesis: Cell Reports KRAS G12V mutation selective requirement for ACSS2 in colorectal adenoma formation: Cell Reports Uncovering new therapeutic targets for a common KRAS mutation behind cancer
Pay in 4 interest-free payments of $6.69 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12




